Predicting breast cancer response to neoadjuvant treatment using multi-feature MRI: results from the I-SPY 2 TRIAL

par Li, Wen, Newitt, David C., Gibbs, Jessica, Wilmes, Lisa J., Jones, Ella F., Arasu, Vignesh A., Strand, Fredrik, Onishi, Natsuko, Nguyen, Alex Anh-Tu, Kornak, John, Joe, Bonnie N., Price, Elissa R., Ojeda-Fournier, Haydee, Eghtedari, Mohammad, Zamora, Kathryn W., Woodard, Stefanie A., Umphrey, Heidi, Bernreuter, Wanda, Nelson, Michael, Church, An Ly, Bolan, Patrick, Kuritza, Theresa, Ward, Kathleen, Morley, Kevin, Wolverton, Dulcy, Fountain, Kelly, Lopez-Paniagua, Dan, Hardesty, Lara, Brandt, Kathy, McDonald, Elizabeth S., Rosen, Mark, Kontos, Despina, Abe, Hiroyuki, Sheth, Deepa, Crane, Erin P., Dillis, Charlotte, Sheth, Pulin, Hovanessian-Larsen, Linda, Bang, Dae Hee, Porter, Bruce, Oh, Karen Y., Jafarian, Neda, Tudorica, Alina, Niell, Bethany L., Drukteinis, Jennifer, Newell, Mary S., Cohen, Michael A., Giurescu, Marina, Berman, Elise, Lehman, Constance, Partridge, Savannah C., Fitzpatrick, Kimberly A., Borders, Marisa H., Yang, Wei T., Dogan, Basak, Goudreau, Sally, Chenevert, Thomas, Yau, Christina, DeMichele, Angela, Berry, Don, Esserman, Laura J., Hylton, Nola M.
Publié dans NPJ Breast Cancer (2020)